Depression in patients with coronary heart disease
The DOI matches its Crossref record.
Abstract
P2Y12 receptor antagonist therapy is recommended in addition to ASA for up to 1 year after acute coronary syndrome to reduce ischemic events. In contrast, the benefit of long-term dual antiplatelet therapy beyond 1 year remains unclear. Ticagrelor is a potent, reversibly binding P2Y12 receptor-antagonist that has been shown to be superior to clopidogrel in patients with acute coronary syndromes for up to 1 year.PEGASUS-TIMI 54 is a randomized, double-blind, placebo-controlled, multinational clinical trial designed to evaluate the efficacy and safety of ticagrelor in addition to aspirin (75-150 mg) for the prevention of major adverse cardiovascular events in patients with a history of myocardial infarction and risk factors. Patients with a history of spontaneous myocardial infarction within 1 to 3 years are randomized in a 1:1:1 fashion to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or matching placebo, all with low dose ASA, until the end of the study. The primary endpoint is a composite of cardiovascular death, myocardial infarction, or stroke. Recruitment began in October 2010 and completed in April 2013 with a sample size of over 21,000 patients. The trial is planned to continue until the latest of either 1,360 adjudicated primary end points are accrued or the last patient randomized has been followed for at least 12 months.PEGASUS-TIMI 54 is investigating whether the addition of intensive antiplatelet therapy with ticagrelor to low-dose aspirin reduces major adverse cardiovascular events in high-risk patients with a history of myocardial infarction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Davidson, K. W., Rieckmann, N., Clemow, L., Schwartz, J. E., Shimbo, D., Medina, V., Albanese, G., Kronish, I., Hegel, M., & Burg, M. M. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.29 · Cited by 350
“The primary outcome was satisfaction with depression care because previous treatments may not have been acceptable to patients with CHD.17 Patients were asked, “Over the last 2 months, how would you rate the quality of professional care you have received for your symptoms of distress or depression?””
ResultInfluentialRollman, B. L., Belnap, B. H., LeMenager, M. S., Mazumdar, S., Houck, P. R., Counihan, P. J., Kapoor, W. N., Schulberg, H. C., & Reynolds, C. F. (2009) · JAMA · doi:10.1001/jama.2009.1670 · Cited by 343
Davidson, K. W., Bigger, J. T., Burg, M. M., Carney, R. M., Chaplin, W. F., Czajkowski, S., Dornelas, E., Duer-Hefele, J., Frasure-Smith, N., Freedland, K. E., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.915 · Cited by 162
“2 million Americans survive an acute coronary syndrome (ACS) event,(4) and many have clinically significant and persistent depression.(5,6) Patients with postACS depression have significantly more ambulatory medical appointments, emergency department visits, and higher health care costs than similar patients without d…”
BackgroundGoldstein, C. M., Gathright, E. C., & Garcia, S. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s127277 · Cited by 138
“Estimates of depression in CVD vary depending on the specific disease processes and assessment method, but ~50% of patients experience major or minor depression at least once in the course of experiencing CVD.(5) In a study that examined individuals hospitalized for myocardial infarction (MI), ~20% met the criteria fo…”
Influential
Metadata
- Authors
- Baloescu, A., Grigorescu, G., Miclos, M., Badescu, E., & Gheorghe, M. D.
- Venue
- European Psychiatry
- Publisher
- Cambridge University Press (CUP)
- Published
- 2007-03
- Volume
- 22
- Pages
- S223
- ISSN
- 0924-9338 (ISSN-L)
- OpenAlex
- W1975088782
- Cited by
- 13
- References
- 0
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Depression in patients with coronary heart disease. https://app.cochat.ai/papers/10.1016/j.eurpsy.2007.01.744
- The paper
- Baloescu, A., Grigorescu, G., Miclos, M., Badescu, E., & Gheorghe, M. D. (2007). Depression in patients with coronary heart disease. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2007.01.744
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.